4.3 Article

Adenosine blocks aminopterin-induced suppression of osteoclast differentiation

期刊

JOURNAL OF BONE AND MINERAL METABOLISM
卷 31, 期 1, 页码 64-70

出版社

SPRINGER JAPAN KK
DOI: 10.1007/s00774-012-0388-7

关键词

Methotrexate; HAT; Monoclonal antibody; Adenosine; Osteoclastogenesis

资金

  1. Japanese Ministry of Education, Science, and Culture [19592116]
  2. Grants-in-Aid for Scientific Research [25670780, 24592806, 19592116] Funding Source: KAKEN

向作者/读者索取更多资源

To search cell surface molecules involved in the regulation of osteoclastogenesis, especially in fusion process, it is one powerful approach to obtain monoclonal antibodies bearing ability to block formation of multinucleated osteoclasts. Ideally, direct bio-assay of hybridoma supernatants is quite convenient to screen monoclonal antibodies of interest from numerous culture wells. However, addition of hybridoma supernatant containing hypoxanthine-aminopterin-thymidine (HAT), components of the selection medium, to whole bone marrow cultures strikingly suppressed osteoclastogenesis. Here we clarified aminopterin is the responsible component in HAT medium to inhibit osteoclastogenesis. Methotrexate (MTX), mono-methylated aminopterin, showed similar suppressive effect on osteoclastogenesis. When bone marrow cells were cultured in the presence of all nucleosides, aminopterin and MTX-induced suppression of osteoclastogenesis was abrogated. Among four nucleosides only adenosine canceled aminopterin-induced suppression of osteoclastogenesis. Direct bio-assay of hybridoma supernatant containing HAT selection medium is now available to screen monoclonal antibodies if adenosine-containing culture medium was utilized for evaluating osteoclastogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据